V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Abbott Laboratories Executive Compensation (FY25)

ABT · Abbott Park, IL · Executive and director compensation, fiscal 2022 to 2025
Data as of September 7, 2026Latest filing (8-K): April 27, 2026
426 figures on this page: 417 cited to the filing that reported them, 9 calculated from figures it prints. See the citations
Robert Ford was paid $24,198,660 in total compensation as Chairman of the Board and Chief Executive Officer for fiscal 2025, and compared with the $22,777,075 reported for fiscal 2024, Ford's total was 6.2% higher. The disclosed chief executive pay ratio for fiscal 2025 is 166:1, against median employee compensation of $145,528. Shareholders recorded 90.3% support for the say-on-pay proposal at the meeting held April 24, 2026 for fiscal 2025. The disclosed peer group names 3M Company, Becton Dickinson, Boeing, Boston Scientific and Bristol-Myers Squibb, among others.
Chief executive, fiscal 2025
◇
Robert Ford
Median of the other named officers
$6,995,583
5 officers, excluding the chief executive
Latest say-on-pay support
=
April 24, 2026
Chief executive pay ratio
◇
To the median employee
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Robert Ford: $22,777,075 → $24,198,660 (6.2% higher)
CEO pay ratio: 177:1 → 166:1 (6.2% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is Abbott Laboratories' chief executive and what were they paid?
Robert Ford was paid $24,198,660 in total compensation as Chairman of the Board and Chief Executive Officer for fiscal 2025. Compared with the $22,777,075 reported for fiscal 2024, Ford's total was 6.2% higher.
What was Abbott Laboratories' say-on-pay result?
Shareholders recorded 90.3% support for the say-on-pay proposal at the meeting held April 24, 2026 for fiscal 2025.
Which companies are in Abbott Laboratories' peer group?
The disclosed peer group names 3M Company, Becton Dickinson, Boeing, Boston Scientific and Bristol-Myers Squibb, among others.
What is Abbott Laboratories' chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2025 is 166:1, against median employee compensation of $145,528.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Robert Ford
Chairman of the Board and Chief Executive Officer
◇—◇◇◇◇◇◇
Robert Funck
Former Executive Vice President, Finance
◇—◇◇◇◇◇◇
Daniel Salvadori
Executive Vice President and Group President, Established Pharmaceuticals and Nutritional Products
◇—◇◇◇◇◇◇
Hubert Allen
Executive Vice President, General Counsel and Secretary
◇—◇◇◇◇◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Robert Ford
Chairman of the Board and Chief Executive Officer
◇—◇◇◇◇◇◇
Robert Funck
Former Executive Vice President, Finance
◇—◇◇◇◇◇◇
Hubert Allen
Former Executive Vice President, General Counsel and Secretary
◇—◇◇◇◇◇◇
Daniel Salvadori
Executive Vice President and Group President, Established Pharmaceuticals and Nutritional Products
◇—◇◇◇◇◇◇
Lisa Earnhardt
Executive Vice President and Group President, Medical Devices
◇—◇◇◇◇◇◇
Philip Boudreau
Executive Vice President, Finance and Chief Financial Officer
◇—◇◇◇◇◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Robert Ford
Chairman of the Board and Chief Executive Officer
◇—◇◇◇◇◇◇
Robert Funck
Former Executive Vice President, Finance
Departed during or after this year
◇—◇◇◇◇◇◇
Philip Boudreau
Executive Vice President, Finance and Chief Financial Officer
◇—◇◇◇◇◇◇
Hubert Allen
Former Executive Vice President, General Counsel and Secretary
◇—◇◇◇◇◇◇
Lisa Earnhardt
Executive Vice President and Group President, Medical Devices
◇—◇◇◇◇◇◇
Daniel Salvadori
Executive Vice President and Group President, Established Pharmaceuticals and Nutritional Products
◇—◇◇◇◇◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Robert Ford
Chairman of the Board and Chief Executive Officer
◇—◇◇◇◇◇◇
Philip Boudreau
Executive Vice President, Finance and Chief Financial Officer
◇—◇◇◇◇◇◇
Lisa Earnhardt
Executive Vice President and Group President, Medical Devices
◇—◇◇◇◇◇◇
Hubert Allen
Former Executive Vice President, General Counsel and Secretary
Departed during or after this year
◇—◇◇◇◇◇◇
Christopher Scoggins
Executive Vice President, Diabetes Care
◇—◇◇◇◇◇◇
Daniel Salvadori
Executive Vice President and Group President, Established Pharmaceuticals and Nutritional Products
◇—◇◇◇◇◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Christopher ScogginsPSU◇——◇——◇
Christopher ScogginsOPTION◇——◇—◇◇
Daniel SalvadoriRSU◇——◇——◇
Daniel SalvadoriOPTION◇——◇—◇◇
Hubert AllenPSU◇——◇——◇
Hubert AllenOPTION◇——◇—◇◇
Lisa EarnhardtPSU◇——◇——◇
Lisa EarnhardtOPTION◇——◇—◇◇
Philip BoudreauOPTION◇——◇—◇◇
Philip BoudreauRSU◇——◇——◇
Robert FordPSU◇——◇——◇
Robert FordOPTION◇——◇—◇◇
Fiscal 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Daniel SalvadoriRSU◇◇——
Option◇—◇—
RSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
RSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Christopher ScogginsRSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
RSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Hubert AllenOption◇—◇—
RSU◇◇——
RSU◇◇——
Option◇—◇—
RSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Lisa EarnhardtRSU◇◇——
Option◇—◇—
Option◇—◇—
RSU◇◇——
Option◇—◇—
Option◇—◇—
RSU◇◇——
Option◇—◇—
Option◇—◇—
Philip BoudreauRSU◇◇——
Option◇—◇—
RSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
RSU◇◇——
Option◇—◇—
RSU◇◇——
Option◇—◇—
Option◇—◇—
Robert FordOption◇—◇—
Option◇—◇—
Option◇—◇—
RSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
RSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Daniel Salvadori
Executive Vice President and Group President, Established Pharmaceuticals and Nutritional Products · Terms as described in the company’s compensation discussion · citing a 2026 filing
Change-in-control multiple◇
Benefits continuation on change in control◇
Excise tax treatment◇
Lisa Earnhardt
Executive Vice President and Group President, Medical Devices · Terms as described in the company’s compensation discussion · citing a 2026 filing
Change-in-control multiple◇
Benefits continuation on change in control◇
Excise tax treatment◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Robert J. Alpern
◇◇——◇◇◇
Nancy McKinstry
◇◇◇—◇—◇
John G. Stratton
Lead independent director
◇◇———◇◇
Sally E. Blount
◇◇——◇◇◇
Claire Babineaux-Fontenot
◇◇———◇◇
Daniel J. Starks
—◇◇———◇
Michael F. Roman
◇◇————◇
Michelle A. Kumbier
◇◇————◇
Paola Gonzalez
◇◇————◇
Darren W. McDew
◇◇————◇
Michael G. O'Grady
—◇◇———◇
Nita Ahuja and Robert B. Ford served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Nominating and governance chair◇
Equity is delivered as restricted stock units.
Stock ownership guideline: 5x annual director fees earned or paid in cash

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • 3M Company MMM
  • Becton Dickinson BDX
  • Boeing BA
  • Boston Scientific BSX
  • Bristol-Myers Squibb BMY
  • Cisco CSCO
  • Danaher Corporation DHR
  • Honeywell International HON
  • Johnson & Johnson JNJ
  • Medtronic MDT
  • Merck MRK
  • Nike NKE
  • PepsiCo PEP
  • Pfizer PFE
  • Procter & Gamble PG
  • Reckitt Benckiser RBGLY
  • Stryker Corporation SYK
  • The Coca-Cola Company KO
  • Thermo Fisher Scientific TMO

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025April 24, 2026=◇◇◇
2024April 25, 2025=◇◇◇
2023April 26, 2024=◇◇◇
2022April 28, 2023=◇◇◇
2021April 29, 2022=◇◇◇
2020April 23, 2021=◇◇◇
2019April 24, 2020=◇◇◇
2018April 26, 2019=◇◇◇
2017April 27, 2018=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Abbott Laboratories files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Abbott Laboratories disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Abbott Laboratories sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Abbott Laboratories' disclosed peer group is defensible, who names Abbott Laboratories back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
426 figures on this page: 417 cited to the filing that reported them, 9 calculated from figures it prints.
417 cited to the filing
9 calculated from the filing

Documents cited

  1. 0001104659-26-049434
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001308179-26-000064
    2025 Grants of plan based awards · 2025 Outstanding equity awards at fiscal year end · CEO Pay Ratio · Compensation Discussion and Analysis · and 2 more sections
  3. 0001104659-25-040201
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001308179-25-000134
    SUMMARY COMPENSATION TABLE
  5. 0001104659-24-054016
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0001308179-24-000182
    SUMMARY COMPENSATION TABLE
  7. 0001104659-23-054706
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0001308179-23-000247
    Summary Compensation Table
  9. 0001104659-22-054704
  10. 0001104659-21-054917
  11. 0001104659-20-052424
  12. 0001104659-19-025282
  13. 0001104659-18-028644
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Abbott Laboratories executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/ABT (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Abbott Laboratories and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Abbott Laboratories discloses

The companies named in ABT's own disclosed peer group.

3M CompanyBecton DickinsonBoeingBoston ScientificBristol-Myers SquibbCiscoHoneywell InternationalJohnson & JohnsonMedtronicMerckNikePfizerProcter & GambleStryker CorporationThe Coca-Cola Company

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  The Pay Desk · Methodology · Terms · Privacy